Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year price target among […]
Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at Chardan Capital theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a strong-buy rating to a buy rating in a report published on Wednesday. A number of other research analysts have also recently commented on ALNY. William Blair restated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, January 8th. […]
Cantor Fitzgerald restated their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note released on Tuesday, Benzinga reports. They currently have a $165.00 price target on the biopharmaceutical company’s stock. Several other research firms also recently weighed in on ALNY. JPMorgan Chase & Co. boosted their target price on […]
Cantor Fitzgerald reiterated their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $165.00 price target on the biopharmaceutical company’s stock. Several other equities analysts have also recently weighed in on ALNY. Needham & Company LLC reiterated a buy […]